Governance Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2025-01-15 EST			5-day change	1st Jan Change
92.38 ^USD	+1.52%		+3.63%	+0.01%

01-15	Gilead Sciences, US government settle patent case over HIV prevention drugs	RE
01-13	Gilead to Seek M&A	CI

Executive Committee: Gilead Sciences, Inc.

Manager

Positions heldSince

Daniel O'Day

59 year

Chief Executive Officer

2019-02-28

Sarah Miksinski

General Counsel

Sandra Patterson

58 year

Comptroller/Controller/Auditor

2023-02-28

Deborah Telman

60 year

General Counsel	2022-07-31
Corporate Secretary	2022-07-31

Flavius Martin

Chief Tech/Sci/R&D Officer

2021-04-11

Jacquie Ross

Investor Relations Contact

2020-12-31

Jyoti Mehra

49 year

Human Resources Officer

2017-10-31

Andrew Dickinson

55 year

Director of Finance/CFO

2019-10-31

Dietmar Berger

Chief Tech/Sci/R&D Officer

2025-01-01

Composition of the Board of Directors: Gilead Sciences, Inc.

Director

CommitteesSince

Daniel O'Day

59 year

Chairman

2019-02-28

Anthony Welters

70 year

Governance Committee
Nominating Committee
Compensation Committee Chair	2015-10-26
Compensation Committee	2020-10-16
HR Committee	2020-10-16
Governance Committee Chair	2021-05-11
Nominating Committee Chair	2021-05-11

Harish M. Manwani

71 year

HR Committee	2018-05-08
Governance Committee	2021-05-11
Nominating Committee	2021-05-11
Compensation Committee	2018-05-08

Ted Love

66 year

Governance Committee Chair
Nominating Committee Chair
Compensation Committee Chair	2023-08-02
Audit Committee	2024-01-31

Kelly Kramer

57 year

Compensation Committee	2020-11-30
HR Committee
Audit Committee Chair	2020-11-30
Audit Committee	2020-01-31

Sandra Horning

76 year

Governance Committee	2020-02-29
Nominating Committee	2020-02-29

Jacqueline Barton

72 year

Compensation Committee	2017-12-31
HR Committee	2017-12-31

Javier Rodriguez

54 year

Audit Committee

2020-06-14

Jeffrey Bluestone

71 year

Executive Committee

2020-04-08

Latest Appointments: Gilead Sciences, Inc.

Gilead Sciences Names Sanofi's Berger as Next Chief Medical Officer	12-12	DJ
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer	12-12	RE
Gilead Sciences Names Dietmar Berger as Chief Medical Officer	12-12	MT
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer	11-18	CI
Savills Appointed by Receivers to Market ?60 Million Dublin Offices Let to WeWork	24-10-31	CI

More news

Former Officers and Directors: Gilead Sciences, Inc.

Insider

Positions held

SinceUntil

Kevin Lofton

Director/Board Member	2009-07-28	2024-05-07
Independent Dir/Board Member	2009-07-28	2024-05-07

Brett Pletcher

Compliance Officer	-	2022-07-31
General Counsel	2011-03-30	2022-07-31
Corporate Officer/Principal	2004-12-31	2011-03-30
Corporate Secretary	-	2022-07-31

Tai Yin Yang

Corporate Officer/Principal

2004-12-31

2022-07-17

Amy E. Flood

Public Communications Contact

2021-05-31

William Lee

Chief Tech/Sci/R&D Officer

1990-12-31

2021-04-11

Richard Whitley

Director/Board Member	2008-06-30	2020-12-31
Independent Dir/Board Member	2008-06-30	2020-12-31

Robin Washington

Comptroller/Controller/Auditor	2008-05-04	2019-10-31
Director of Finance/CFO	2008-05-04	2019-10-31

Gregg Alton

Chief Executive Officer	2018-12-31	2019-02-28
Compliance Officer	1998-12-31	-
Public Communications Contact	2009-08-03	2012-05-08
General Counsel	1998-12-31	2009-08-03
Corporate Officer/Principal	2019-02-28	2019-10-03
Corporate Secretary	1998-12-31	-

John McHutchison

Chief Tech/Sci/R&D Officer	2018-02-28	2019-08-01
Corporate Officer/Principal	2010-06-07	2018-02-28

John Martin

Chief Executive Officer	1995-12-31	2016-03-09
Chairman	2008-05-31	2019-02-28

John Milligan

Director/Board Member	2016-01-27	2018-12-30
Chief Executive Officer	2016-03-09	2018-12-30
Chief Operating Officer	2006-12-31	2016-03-09
President	2007-12-31	2018-12-30

Andrew Cheng

Chief Tech/Sci/R&D Officer	-	2018-09-06
Corporate Officer/Principal	1998-12-31	-

Norbert W. Bischofberger

Chief Tech/Sci/R&D Officer	1994-12-31	2018-04-29
Corporate Officer/Principal	1990-07-31	1994-12-31

James Meyers

Corporate Officer/Principal

1995-12-31

2018-02-21

John Madigan

Director/Board Member	2005-11-30	2017-05-09
Independent Dir/Board Member	2011-07-21	2017-05-09

Paul Carter

Corporate Officer/Principal

2006-03-31

2016-07-31

Kevin B. Young

Corporate Officer/Principal	2004-08-31	2014-02-03
Chief Operating Officer	2016-05-23	-

Gordon Earle Moore

Director/Board Member	1995-12-31	2013-05-30
Independent Dir/Board Member	2011-07-21	2013-05-30

James M. Denny

Director/Board Member	1995-12-31	2013-05-30
Independent Dir/Board Member	2011-07-21	2013-05-30

Susan T. Hubbard

Investor Relations Contact

1989-08-31

2012-05-31

Alan Montgomery

Corporate Officer/Principal

2006-07-31

2011-04-30

Anthony D. Caracciolo

Corporate Officer/Principal

1996-12-31

2010-09-30

Per Wold-Olsen

Director/Board Member	2010-01-27	-
Independent Dir/Board Member	2010-01-27	-

Louis Lange

Corporate Officer/Principal

2009-04-19

Seigo Izumo

Corporate Officer/Principal

2008-08-31

Caroline Dorsa

Director of Finance/CFO

2007-11-04

2008-01-16

Howard Rosen

Corporate Officer/Principal

2003-12-31

2007-12-31

Carla A. Hills

Director/Board Member	2006-12-31	-
Independent Dir/Board Member	2011-07-21	-

Kristen M. Metza

Human Resources Officer

2005-12-31

Steven Fife

Comptroller/Controller/Auditor

2004-12-31

2005-12-31

John Francis Cogan

Director/Board Member	2005-06-30	-
Independent Dir/Board Member	2005-06-30	-

Nicholas G. Moore

Director/Board Member	2004-02-29	-
Independent Dir/Board Member	2004-02-29	-

Karl G. Trass

General Counsel

2002-12-31

2003-06-30

James Sapirstein

Sales & Marketing

2000-05-31

2002-05-31

Rebecca Coleman

Director/Board Member

2000-01-01

Michael W. Aguiar

Director of Finance/CFO

2001-12-31

Robert L. Simon

General Counsel

2000-06-30

2001-11-30

Gayle Edlund Wilson

Director/Board Member	2001-09-30	-
Independent Dir/Board Member	2001-09-30	-

Jeff Bird

Corporate Officer/Principal

1999-12-31

Kenneth Cundy

Corporate Officer/Principal

1991-12-31

1999-12-31

Mark D. Matteucci

Corporate Officer/Principal

1987-12-31

1998-12-31

Louis C. Bock

Corporate Officer/Principal

1989-08-31

Robert J. Stagg

Chief Tech/Sci/R&D Officer

1993-07-31

1996-11-30

Bill Harris

Director of Finance/CFO

1989-12-31

1995-12-31

Michael Bigham

Chief Operating Officer	1987-12-31	1995-12-31
Director of Finance/CFO	1987-12-31	1995-12-31

George Pratt Shultz

Director/Board Member

1995-12-31

John Latham

Corporate Officer/Principal

1988-12-31

1993-12-31

Étienne Francois Davignon

Director/Board Member	1990-08-31	-
Independent Dir/Board Member	2011-07-21	-

John J. Toole

Corporate Officer/Principal

1990-03-31

Akram Bouchenaki

Corporate Officer/Principal

Nicholas S. Hellmann

Corporate Officer/Principal

Joseph M. Baini

Corporate Officer/Principal

Wenjin Yang

Corporate Officer/Principal

James V. Desiderio

Corporate Officer/Principal

Jim Ziegler

Sales & Marketing

George Tidmarsh

Corporate Officer/Principal

Erin Edgley

Public Communications Contact

Patrick O'Brien

Investor Relations Contact

Sunil Patel

Corporate Officer/Principal

Dirk B. Mendel

Corporate Officer/Principal

Jeffrey Rudy

Corporate Officer/Principal

Gulshan H. Shaver

Corporate Officer/Principal

Gary C. Visor

Corporate Officer/Principal

Roger G. Mills

Corporate Officer/Principal

Julie Cherrington

Corporate Officer/Principal

Cordell W. Hull

Director/Board Member

David Brogan

Corporate Officer/Principal

Jeffery P. Davis

Corporate Officer/Principal

Mark Italia

General Counsel

Richard J. Gorczynski

Corporate Officer/Principal

Pamela Goss

Corporate Officer/Principal

Adam Tomasi

Corporate Officer/Principal

Robert L. St. Claire

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	21
Female	10

Of which Executive Committee

Male	5
Female	4

Of which Directors

Male	8
Female	1

ESG MSCI

AAA

ESG

Environment

Social

Governance

Controversy

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Employees

18,000

Sector

Pharmaceuticals

Calendar

2025-02-11 - Q4 2024 Earnings Release

More about the company